Sigma Planning Corp’s Altamira Therapeutics Ltd CYTO Stock Holding History

Sigma Planning Corp’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2	Closed	-$6K	–	1057
2019 Q1	$6K	Buy	+2	New	+$6.43K	﹤0.01%	940
2018 Q1	–	Sell	-1	Closed	-$32K	–	925
2017 Q4	$32K	Hold	1	–	–	﹤0.01%	847
2017 Q3	$35K	Buy	+1	New	+$60.9K	﹤0.01%	841
2017 Q2	–	Hold	0	–	–	–	784
2017 Q1	–	Hold	0	–	–	–	770
2016 Q4	–	Hold	0	–	–	–	729
2016 Q3	–	Hold	0	–	–	–	738

Other funds holding CYTO

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Sigma Planning Corp's CYTO Position: Q2 2019 in Review

Sigma Planning Corp sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2019, closing a stake of 2 shares — an estimated $6K sold.

Sigma Planning Corp first reported a position in CYTO in Q3 2017 and held it in 3 quarters. The position peaked at $35K in Q3 2017. 5 funds tracked by Wall St. Rank hold CYTO as of Q2 2019.

Sigma Planning Corp reported no remaining Altamira Therapeutics Ltd position as of Q2 2019 after selling out during the quarter.
Sigma Planning Corp sold 2 Altamira Therapeutics Ltd shares in Q2 2019, an estimated $6K.
Sigma Planning Corp first reported a position in Altamira Therapeutics Ltd in Q3 2017 and held it in 3 quarters.
Sigma Planning Corp's Altamira Therapeutics Ltd position peaked at $35K in Q3 2017.
5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2019.

Based on Sigma Planning Corp's 13F filing for Q2 2019, filed 1 Aug 2019.